The full clinical results of the only trial of SQ3370, posted before peer review. The treatment was well tolerated at very high doses, but 2 of 14 sarcoma patients responded, about what ordinary doxorubicin achieves, and the trial was stopped.
A preprint, posted on medRxiv on 3 June 2025 and not peer reviewed when read, reporting both parts of NCT04106492. Treatment was an injection of the biopolymer SQL70 into a tumour followed by three or five consecutive daily infusions of the doxorubicin prodrug SQP33. The primary endpoints were treatment-emergent adverse events, dose-limiting toxicities and the recommended phase 2 dose; pharmacokinetics, efficacy and immune profiling were secondary.
Phase 1 enrolled 39 patients. SQ3370 at 0.38 to 15 times the standard doxorubicin dose was well tolerated, with no dose-limiting toxicity reported and mild and manageable myelosuppression. Doxorubicin was released rapidly at every dose level, with exposure rising up to 15 times the standard dose, and 12 times was selected as the recommended phase 2 dose.
Phase 2a enrolled 14 patients with soft tissue sarcoma at that dose. The unconfirmed objective response rate was 14.3 per cent (2 of 14) and the disease control rate 71.4 per cent (10 of 14; 95% CI 41.9 to 91.6). Immune profiling showed expansion and activation of cytotoxic CD8 T cells, and tumours shrank in non-injected as well as injected lesions. The study was terminated because the prespecified criterion for continuing, an objective response rate greater than that of standard doxorubicin, was not met.
For a person with sarcoma, this is a treatment that was easier to tolerate than its dose would suggest but did not work better than doxorubicin in the small group tested, and it is not available. For the field, it is the human proof that click activation works as chemistry, which is why the company has moved to versions guided by tumour-binding proteins.
Shares Sant P. Chawla, SQ3370 in advanced solid tumours and soft tissue sarcoma (SQ3370-001, phase 1/2a), SQ3370, Shasqi.
Shares SQ3370, Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares SQ3370, Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares SQ3370, Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares Sant P. Chawla, SQ3370 in advanced solid tumours and soft tissue sarcoma (SQ3370-001, phase 1/2a), Sarcomas (soft tissue, bone, GIST).
Shares SQ3370 in advanced solid tumours and soft tissue sarcoma (SQ3370-001, phase 1/2a), SQ3370.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/